Optimal, Interpretable, and Personalized Immune Checkpoint Inhibitor Duration in Non‐Small Cell Lung Cancer: A Multicenter Real‐World Study
Siqi Wang, Jianhua Liu, Qiang Nie, Ruichuan Shi, Nan Xu, Qianqian He, Guanchao Ye, Jingyi Liu, Qiuyang Hou, Kexue Deng, Lu Wang, Taixue An · 2026
Read Optimal, Interpretable, and Personalized Immune Checkpoint Inhibitor Duration in Non‐Small Cell Lung Cancer: A Multicenter Real‐World Study by Siqi Wang, Jianhua Liu, Qiang Nie, Ruichuan Shi, Nan Xu, Qianqian He, Guanchao Ye, Jingyi Liu, Qiuyang Hou, Kexue Deng, Lu Wang, Taixue An (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13620853.txt.
Description
Siqi Wang and fourteen colleagues tackled a practical question in lung cancer care: how long should immune checkpoint inhibitor treatment run for each patient? Nobody knows the ideal duration for these drugs in non-small cell lung cancer. Their multicenter study gathered 1,054 patients from hospitals in China and the United States. The team built a decision tree on a training group, using a counterfactual method to estimate what each duration would have done.
The tree sorted patients into seven subgroups with distinct patterns. Roughly two fifths of patients fared better in survival terms with short courses, while a similar share fared better with long courses. A smaller slice seemed to gain little from dragging treatment out. Because the tree uses ordinary clinical data and shows its reasoning openly, the authors offer it as a planning aid that prospective trials should now test.
Catalog record
| CREATOR | Siqi Wang, Jianhua Liu, Qiang Nie, Ruichuan Shi, Nan Xu, Qianqian He, Guanchao Ye, Jingyi Liu, Qiuyang Hou, Kexue Deng, Lu Wang, Taixue An |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |